Rossari Biotech Ltd (IN:ROSSARI)
:ROSSARI
Want to see IN:ROSSARI full AI Analyst Report?
Top Page
Rossari Biotech Ltd
(ROSSARI)
Select Model
Select Model
Rating:64Neutral
Price Target:
₹552.00
▼(-5.47% Downside)
Action:DowngradedDate:03/14/26
The score is driven primarily by solid fundamentals (growth, improving profitability, and low leverage), partially offset by negative free cash flow. Technicals are notably weak with the stock below key moving averages and bearish momentum indicators, while valuation is mixed with a mid-to-high P/E and minimal dividend support.
Positive Factors
Revenue & margin expansion
Consistent revenue growth (13.65% YoY) alongside improved gross and EBIT margins demonstrates durable product acceptance and pricing power across customers. This suggests scalable operations and the ability to convert sales into sustainable profitability, supporting reinvestment and long-term competitiveness.
Negative Factors
Negative free cash flow
Persistently negative free cash flow reduces internal funding for growth and increases dependence on external financing or equity. Over several months this can constrain strategic flexibility, slow organic expansion, and limit scope for shareholder returns if capex intensity remains elevated versus operating cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & margin expansion
Consistent revenue growth (13.65% YoY) alongside improved gross and EBIT margins demonstrates durable product acceptance and pricing power across customers. This suggests scalable operations and the ability to convert sales into sustainable profitability, supporting reinvestment and long-term competitiveness.
Read all positive factors
Rossari Biotech Ltd (ROSSARI) vs. iShares MSCI India ETF (INDA)
Market Cap
₹28.59B
Dividend Yield0.09%
Average Volume (3M)2.66K
Price to Earnings (P/E)24.6
Beta (1Y)0.89
Revenue Growth16.09%
EPS Growth1.02%
CountryIN
Employees450
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)N/A
Shares Outstanding55,383,366
10 Day Avg. Volume1,386
30 Day Avg. Volume2,661
Financial Highlights & Ratios
PEG Ratio5.98
Price to Book (P/B)2.88
Price to Sales (P/S)1.64
P/FCF Ratio-161.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)28.74
Revenue Forecast (FY)₹26.14B
Rossari Biotech Ltd Business Overview & Revenue Model
Company Description
Rossari Biotech Limited engages in manufacture and sale of specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; and water treatment solutions. The...
How the Company Makes Money
Rossari Biotech primarily makes money by selling specialty chemical products and formulations to other businesses (B2B). Revenue is generated through: (1) Product sales across its key end-user segments—where the company supplies application-specif...
Rossari Biotech Ltd Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
75
Positive
Cash Flow
68
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.22B | 20.80B | 18.31B | 16.56B | 14.83B | 7.07B |
| Gross Profit | 6.42B | 6.47B | 5.26B | 2.80B | 2.29B | 2.29B |
| EBITDA | 2.77B | 2.65B | 2.57B | 2.12B | 1.94B | 1.31B |
| Net Income | 1.37B | 1.36B | 1.31B | 1.07B | 976.74M | 802.20M |
Balance Sheet | ||||||
| Total Assets | 20.88B | 18.96B | 15.72B | 13.68B | 12.57B | 5.61B |
| Cash, Cash Equivalents and Short-Term Investments | 719.76M | 1.14B | 667.85M | 1.52B | 644.26M | 883.57M |
| Total Debt | 3.53B | 2.18B | 1.19B | 739.28M | 84.27M | 0.00 |
| Total Liabilities | 8.36B | 7.11B | 5.24B | 4.52B | 4.52B | 1.53B |
| Stockholders Equity | 12.51B | 11.85B | 10.48B | 9.15B | 8.05B | 4.09B |
Cash Flow | ||||||
| Free Cash Flow | -1.67B | -210.69M | -880.28M | 1.20B | -88.67M | -103.17M |
| Operating Cash Flow | -250.32M | 1.37B | 432.55M | 1.52B | 293.58M | 477.67M |
| Investing Cash Flow | -1.06B | -1.84B | -1.03B | -1.81B | -2.99B | -371.79M |
| Financing Cash Flow | 1.22B | 649.01M | 161.85M | 608.55M | 2.92B | -245.92M |
Rossari Biotech Ltd Technical Analysis
Neutral
583.95
Price Trends
472.68
Positive
523.62
Negative
590.90
Negative
Market Momentum
2.62
Negative
65.68
Neutral
94.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ROSSARI, the sentiment is Neutral. The current price of 583.95 is above the 20-day moving average (MA) of 430.72, above the 50-day MA of 472.68, and below the 200-day MA of 590.90, indicating a neutral trend. The MACD of 2.62 indicates Negative momentum. The RSI at 65.68 is Neutral, neither overbought nor oversold. The STOCH value of 94.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ROSSARI.
Rossari Biotech Ltd Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹26.69B | 23.71 | ― | 0.65% | 2.07% | -16.12% | |
64 Neutral | ₹28.59B | 24.59 | ― | 0.09% | 16.09% | 1.02% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
61 Neutral | ₹23.20B | 23.16 | ― | 0.02% | 5.46% | -27.45% | |
57 Neutral | ₹23.79B | 0.22 | ― | ― | -19.38% | 1266.07% | |
39 Underperform | ₹23.95B | 172.94 | ― | ― | -21.80% | -668.13% |
* Basic Materials Sector Average
IN:ROSSARI
Rossari Biotech Ltd
506.15
-184.78
-26.74%
IN:BHARATRAS
Bharat Rasayan Limited
1,396.65
-999.28
-41.71%
IN:FCL
Fineotex Chemical Limited
23.09
-1.14
-4.70%
IN:KIRIINDUS
Kiri Industries Limited
414.15
-178.65
-30.14%
IN:ORISSAMINE
Orissa Minerals Development Company Limited
4,067.80
-1,177.65
-22.45%
IN:RPEL
Raghav Productivity Enhancers Ltd.
686.20
45.27
7.06%
Rossari Biotech Ltd Corporate Events
Rossari Biotech Reschedules Subsidiaries’ Capacity Expansion in Phased Rollout
Apr 23, 2026
Rossari Biotech has announced that its material subsidiaries, Unitop Chemicals and Tristar Intermediates, are re-evaluating their previously disclosed capacity expansion plans in response to changing business requirements and market conditions. As...
Rossari Biotech to Host Q4 FY26 Earnings Call on April 28
Apr 21, 2026
Rossari Biotech Ltd has scheduled an earnings conference call for investors and analysts on Tuesday, April 28, 2026, at 5:00 p.m. IST to discuss its financial results for the fourth quarter and full year ended March 31, 2026. The call will open wi...
Rossari Subsidiary Unitop Chemicals to Sell Non-Core Mumbai Office for Rs 10 Crore
Apr 3, 2026
Rossari Biotech has disclosed that the board of its material subsidiary, Unitop Chemicals Private Limited, has approved the sale of an office premises in Saki Naka, Mumbai, for approximately Rs 10 crore. The transaction is expected to be completed...
Rossari Biotech Renames Dubai Subsidiary to Comply With DMCC Norms
Mar 24, 2026
Rossari Biotech has announced that its wholly owned subsidiary Rossari Global DMCC has changed its name to Rossari Global FZCO, effective March 23, 2026, following a certificate issued by the Dubai Multi Commodities Centre Authority. The change is...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.